These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27449546)

  • 41. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
    Stamp LK; Merriman TR; Barclay ML; Singh JA; Roberts RL; Wright DF; Dalbeth N
    Semin Arthritis Rheum; 2014 Oct; 44(2):170-4. PubMed ID: 24925693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
    Singh JA; Yang S; Saag KG
    J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
    Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Uricosuric medications for chronic gout.
    Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010457. PubMed ID: 25392987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum urate goal attainment and associated factors in Chinese gout patients.
    Guo G; Dong C; Yin R; Yang Y; Zhao R; Wang Y; Guo J; Zhou W; Lu G
    Psychol Health Med; 2020 Sep; 25(8):931-939. PubMed ID: 31870173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study.
    Rees F; Jenkins W; Doherty M
    Ann Rheum Dis; 2013 Jun; 72(6):826-30. PubMed ID: 22679303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
    Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
    J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
    Altan A; Shiozawa A; Bancroft T; Singh JA
    J Clin Rheumatol; 2015 Dec; 21(8):411-8. PubMed ID: 26580304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting allopurinol response in patients with gout.
    Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
    Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are Doctors the Best People to Manage Gout? Is There a Role for Nurses and Pharmacists?
    Latif Z; Abhishek A
    Curr Rheumatol Rep; 2018 Mar; 20(3):14. PubMed ID: 29516289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changing paradigms in the management of gout.
    Nuki G; Riches P
    J R Coll Physicians Edinb; 2020 Jun; 50(2):124-132. PubMed ID: 32568281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.